Dengue's hard year: how 2026 broke the vaccine field's momentum — and what happens now
Brazil suspended the world's first single-dose dengue vaccine after two deaths under investigation. Sanofi is exiting the market entirely. The US is about to have zero licensed dengue vaccines. Inside the most turbulent year in flavivirus history.
The archive in the attic: what this domain's first tenant knew about dengue twenty years early
Before it was a newsroom, hibiotech.com was the home of a Hawaiian dengue vaccine developer. Its press archive — 59 releases spanning 2002 to 2016 — reads like a rough draft of today's flavivirus headlines. We're restoring it.
Qdenga's long shadow: the world's most consequential vaccine that America won't touch
Takeda's two-dose shot is carrying national programs on four continents — while staying unapproved in the country that helped invent modern vaccinology. Why the gap is unlikely to close.
mRNA's second act arrives, and it looks like a flu shot
The FDA has approved the first mRNA influenza vaccine. The combo COVID-plus-flu jab data is next, and a bird-flu pandemic trial is already running. The technology's post-COVID chapter finally has product in it.
